October 11, 2011European Heart JournalOpen Access

Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant

View Full Paper

Ask AI

Bookmark

Population

Patients with familial amyloid polyneuropathy associated with the transthyretin Thr60Ala variant

Design

Case_series

Authors

PSPrayman SattianayagamRoyal Free London NHS Foundation Trust AHAngelika F. HahnWestern University CWCarol WhelanHeart Failure & Transplant

Discussion

Member takes

Implication

Details cardiac phenotype in T60A variant; hypothesis-generating and should not yet change practice.

Structured PICO

Population

Patients with familial amyloid polyneuropathy (FAP) associated with the transthyretin (TTR) Thr60Ala (T60A) variant

Outcome

Cardiac phenotype and clinical outcome

This study characterizes the cardiac phenotype and clinical outcomes of the TTR Thr60Ala (T60A) variant, the most common cause of familial amyloid polyneuropathy in the UK.

Cite This Study

Sattianayagam et al. (2011) studied this question.

synapsesocial.com/papers/69fe79d2d8476229fea35a47 https://doi.org/10.1093/eurheartj/ehr383

View Full Paper

Ask AI

Bookmark

Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider